Abbott narrows full-year financial guidance amid strength in medical device sales
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
TD Cowen Reiterates Buy Rating on Abbott Labs (ABT)
October 16, 2024 4:18 PM EDTTD Cowen analyst Joshua Jennings reiterated a Buy rating and $130.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "ABT Posted Another Good Quarter: Third-quarter revenue of $10.64B and EPS of $1.21 exceeded Street forecasts of $10.55B and $1.20. Sales increased 4.9% on a reported basis and were up 7.6% on an organic basis including Covid test sales of $265M, which... More
JPMorgan Reiterates Overweight Rating on Abbott Labs (ABT)
October 16, 2024 4:12 PM EDTJPMorgan analyst Robbie Marcus reiterated an Overweight rating and $135.00 price target on Abbott Labs (NYSE: ABT)
The analyst comments "We like the setup for Abbott going forwards into 2025+ the quarter wasnt perfect, but we saw a strong Devices print and Covid testing upside offset 1x channel destocking in OUS... More
Abbott Labs (ABT) PT Raised to $125 at Jefferies
October 16, 2024 4:04 PM EDTJefferies analyst Matthew Taylor raised the price target on Abbott Labs (NYSE: ABT) to $125.00 (from $120.00) while maintaining a Hold rating.
The analyst comments "ABT reported 3Q24 sales of $10.6B vs. cons. $10.55B, driven by MedTech outperformance/COVID tests, partially offset by softness in... More
Abbott Labs (ABT) PT Raised to $130 at Stifel
October 16, 2024 3:21 PM EDTStifel analyst Rick Wise raised the price target on Abbott Labs (NYSE: ABT) to $130.00 (from $125.00) while maintaining a Buy rating.
The analyst comments "Bottom Line: As 2025 approaches, during today's earnings call, Abbott management encouragingly suggested that the company is well-positioned for more-of-the-same high-singledigit revenue... More
Abbott Labs (ABT) PT Raised to $128 at Evercore ISI
October 16, 2024 2:42 PM EDTEvercore ISI analyst Vijay Kumar raised the price target on Abbott Labs (NYSE: ABT) to $128.00 (from $124.00) while maintaining a Outperform rating.
The analyst comments "Thesis Update: ABTs overall organic (ex COVID) of 8.2% was below recent trends (1H org grew ~10%), mostly due to one off issues in International Nutrition & Core Lab within Dx. On the Nutrition side, ABT lost some share in a specific geography and as a result took down channel inventory. On Dx side, China VBP (was expected) finally went into effect in 3Q along with price... More
